Stockreport

MaxCyte and Kamau Therapeutics sign platform license agreement [Yahoo! Finance]

MaxCyte, Inc.  (MXCT) 
PDF In exchange, MaxCyte will receive annual licensing fees along with programme-related revenue. Kamau's approach to therapy development involves high-efficiency targete [Read more]